stockrowBiogen Inc.
BIIB Healthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024.
- Revenue
- +10.6%
- EPS
- −104.4%
- Free cash flow
- −69.3%
- Total debt
- +16.0%
Quarter to September 2026, against a year earlier
Follow BIIB
Alert me
Biogen Inc. 10-Q filed Oct 28, 2026
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 29, 2026: 26 added · 19 removed · 90 modified; 62 with only figures updated; 2 moved without change
-
Modified · INTERNATIONAL TRADE
The U.S. Secretary of Commerce previously initiated an investigation to determine the effects on the national security of imports of pharmaceuticals and pharmaceutical ingredients, including finished drug products, medical countermeasures, critical inputs such as active pharmaceutical ingredients, key starting materials and derivative products of those items, under Section 232 of the Trade Expansion Act of 1962. In April 2026 after the investigation concluded, the U.S. Administration issued a Proclamation imposing a 100% tariff on imports of patented pharmaceuticals, biologics and associated ingredients, subject to certain exemptions and reduced rates. The Proclamation tariffs
are effectivewent into effect for certain categories on July 31, 2026, and others on September 29, 2026.